(1S,2R,4R)-2-aminobicyclo<2.2.1>heptane hydrochloride | 65481-69-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (1S,2R,4R)-2-aminobicyclo<2.2.1>heptane hydrochloride
• 英文别名: rac-(1S,2R,4R)-bicyclo[2.2.1]heptan-2-amine hydrochloride；endo-2-aminonorbornane hydrochloride；(1S,2R,4R)-2-aminobicyclo[2.2.1]heptane hydrochloride；(1S,2R,4R)-Bicyclo[2.2.1]heptan-2-amine hydrochloride；(1S,2R,4R)-bicyclo[2.2.1]heptan-2-amine;hydrochloride
• CAS: 65481-69-8
• 化学式: C₇H₁₃N*ClH
• 分子量: 147.648
• InChiKey: IZZMPZQAQTXAHW-FNCXLRSCSA-N

物化性质

• 熔点：
  295 °C (dec.)(lit.)

计算性质

• 辛醇/水分配系数(LogP)：
  1.56
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  (1S,2R,4R)-2-aminobicyclo<2.2.1>heptane hydrochloride 、 甲酸乙酯 以51%的产率得到
  参考文献：
  名称：

  LANGHALS, H.;RANGE, G.;WISTUBA, E.;RUECHARDT, C., CHEM. BER., 1981, 114, N 12, 3813-3830

  摘要：

  DOI：
• 作为产物：
  描述：

  (1S,2R,4R)-bicyclo[2.2.1]heptane-2-isocyanate 在 盐酸 作用下， 以 xylene 为溶剂， 生成 (1S,2R,4R)-2-aminobicyclo<2.2.1>heptane hydrochloride
  参考文献：
  名称：

  新型钾通道开放剂：外消旋和旋光的N-（6-氨基-3-吡啶基）-N'-双环烷基-N”-氰基胍衍生物的制备和药理学评价。

  摘要：

  先前的论文报道了N-（6-氨基-3-吡啶基）-N'-双环烷基-N“-氰基胍衍生物的合成和药理学评价，从中选择了三种化合物作为有效的钾通道开放剂。目前的研究中，对所选化合物进行了钾诱导的大鼠主动脉收缩拮抗作用，血压正常大鼠的降压活性以及自发性高血压大鼠的利尿活性的测试，从而进一步评估了化合物（+/-）-10和选择（ +）-N-（6-氨基-3-吡啶基）-N'-[（1S，2R，4R）-双环-[2.2.1]庚-2-基] -N“-氰基胍（（+- 10）（AL0670）开发用作抗高血压药。尽管AL0670被视为吡那地尔型K（+）通道开放剂，但它显示出与吡那地尔不同的药理和构象特征。

  DOI：

  10.1021/jm00039a011

文献信息

• METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT
  申请人：Stover Richard R.

  公开号：US20080175891A1

  公开（公告）日：2008-07-24

  The present invention provides transdermal administration of AICA riboside, or a prodrugs, analogs, or salts thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit includes a patient with decreased left ventricular function, a patient with a prior myocardial infarction, a patient undergoing non-vascular surgery, or a fetus during labor and delivery.

  本发明提供了通过经皮途径给予AICA核糖苷，或其前药、类似物或盐，和/或血液凝块抑制剂以预防或减少患者的不良副作用。可能受益的患者类型包括左心室功能减退的患者、先前发生心肌梗死的患者、接受非血管手术的患者，或分娩期间的胎儿。
• PYRIMIDINE COMPOUND
  申请人：Matsushima Yuji

  公开号：US20110053912A1

  公开（公告）日：2011-03-03

  A novel and excellent method for preventing and/or treating diseases related to a cannabinoid type 2 receptor, based on an agonistic action on a cannabinoid type 2 receptor. It was found that a hetero ring derivative mainly having two substituents, for example, a pyrimidine-5-carboxamide derivative having a substituent amino group at the 2-position, exhibits a potent agonistic action on a cannabinoid type 2 receptor, and can be an agent for preventing and/or treating diseases related to a cannabinoid type 2 receptor such as inflammatory diseases, pain, and the like.

  一种预防和/或治疗与大麻素2型受体相关疾病的新颖优秀方法，基于对大麻素2型受体的激动作用。发现一种异核环衍生物主要具有两个取代基，例如，在2-位置具有取代基氨基的嘧啶-5-羧酰胺衍生物，表现出对大麻素2型受体的强效激动作用，可以成为预防和/或治疗与大麻素2型受体相关疾病，如炎症性疾病、疼痛等的药物。
• Methods, Compositions, and Formulations for Preventing or Reducing Adverse Effects in a Patient
  申请人：Mangano T. Dennis

  公开号：US20060293273A1

  公开（公告）日：2006-12-28

  The present invention provides methods, compositions, formulations, and kits related to acadesine, or a prodrug, analog, or salt thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit includes a patient with decreased left ventricular function, a patient with a prior myocardial infarction, a patient undergoing non-vascular surgery, or a fetus during labor and delivery.

  本发明提供了与阿卡德西酮、其前药、类似物或盐有关的方法、组合物、配方和试剂盒，以及/或用于预防或减少患者不良副作用的血凝抑制剂。可能受益的患者类型包括左心室功能下降的患者、先前发生心肌梗死的患者、接受非血管手术的患者或分娩期间的胎儿。
• Cycloalkyl-Substituted Imidazole Derivative
  申请人：Nagata Tsutomu

  公开号：US20130022587A1

  公开（公告）日：2013-01-24

  A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R 1 , R 2 , and R 3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R 4 represents a hydrogen atom or a prodrug group; and Y represents —CH 2 —CHR 5 —CH 2 —NHR 6 (wherein R 5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R 6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.

  以下是通式（I）所代表的化合物或其药学上可接受的盐，其中A代表一个C3到C12的环烷基，该环烷基可以被一个到三个选自氟基、羟基、C1到C6烷基等的基团所取代；R1、R2和R3各自独立地代表氢原子、氟基或C1到C6烷基；R4代表氢原子或前药基团；Y代表—CH2—CHR5—CH2—NHR6（其中R5代表氢原子、C1到C6烷基或C1到C6烷氧基，R6代表氢原子或前药基团）等，具有极好的TAFIa抑制活性，是治疗心肌梗死、心绞痛、急性冠状动脉综合征、脑梗死、深静脉血栓形成、肺栓塞等疾病的治疗药物。
• Basic acyl amides of (5-amino-1,3-dialkylpyrazol-4-yl)(aryl)methanones, processes for their production, and pharmaceutical compositions containing such compounds
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0068806A2

  公开（公告）日：1983-01-05

  Basic acylamides of (5-amino-1,3-dialkylpyrazol-4-yl)-(aryl)methanones and their pharmaceutically acceptable salts are provided, which have the formula: where the radicals are as defined in the specification. These compounds are useful for treating psychoses. Also provided are processes for preparing the compounds of the invention, and pharmaceutical compositions containing these compounds.

  本发明提供了(5-氨基-1,3-二烷基吡唑-4-基)-(芳基)甲酮的碱性酰酰胺及其药学上可接受的盐，其式为： 其中基团如说明书中所定义。 这些化合物可用于治疗精神病。 还提供了制备本发明化合物的工艺和含有这些化合物的药物组合物。